ATE322900T1 - Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren - Google Patents

Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren

Info

Publication number
ATE322900T1
ATE322900T1 AT97930879T AT97930879T ATE322900T1 AT E322900 T1 ATE322900 T1 AT E322900T1 AT 97930879 T AT97930879 T AT 97930879T AT 97930879 T AT97930879 T AT 97930879T AT E322900 T1 ATE322900 T1 AT E322900T1
Authority
AT
Austria
Prior art keywords
glucosesylceramidase
inhibitors
deoxynojirimycin
deoxynojirimycin derivatives
derivatives
Prior art date
Application number
AT97930879T
Other languages
English (en)
Inventor
Johannes Maria Franciscu Aerts
Meibergdreef
Upendra Kumar Pandit
Gerrit Jan Koomen
Herman Steven Overkleeft
Paola Vianello
Original Assignee
Macrozyme Dnm B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrozyme Dnm B V filed Critical Macrozyme Dnm B V
Application granted granted Critical
Publication of ATE322900T1 publication Critical patent/ATE322900T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
AT97930879T 1996-07-15 1997-07-14 Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren ATE322900T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96202010 1996-07-15

Publications (1)

Publication Number Publication Date
ATE322900T1 true ATE322900T1 (de) 2006-04-15

Family

ID=8224192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930879T ATE322900T1 (de) 1996-07-15 1997-07-14 Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren

Country Status (9)

Country Link
US (1) US6177447B1 (de)
EP (1) EP0912179B1 (de)
JP (5) JP4564108B2 (de)
AT (1) ATE322900T1 (de)
AU (1) AU732552B2 (de)
CA (1) CA2260790C (de)
DE (1) DE69735669T2 (de)
IL (1) IL128036A (de)
WO (1) WO1998002161A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20010031741A1 (en) * 2000-02-17 2001-10-18 Robin Ziegler Methods for treatment of lysosomal storage diseases
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2002348971A1 (en) * 2001-10-12 2003-04-28 Stefana M. Petrescu Ph-sensitive liposomes for targeted drug delivery
AU2003248960B2 (en) 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
ES2393331T3 (es) 2002-07-17 2012-12-20 Actelion Pharmaceuticals Ltd. Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
PL1680112T3 (pl) * 2003-10-29 2011-05-31 Genzyme Corp N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
US20050137223A1 (en) * 2003-11-12 2005-06-23 Amicus Therapeutics, Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
WO2005063706A1 (en) * 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
WO2005123055A2 (en) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
DE602007008870D1 (de) 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
US8426395B2 (en) * 2008-05-30 2013-04-23 Northern Northern Innovations Holding Corp Preparations containing creatine and imino sugars
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
CA2875975A1 (en) * 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars
ES2895490T3 (es) * 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US10239830B2 (en) * 2015-02-11 2019-03-26 Icahn School Of Medicine At Mount Sinai Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2925943A1 (de) * 1979-06-27 1981-01-29 Bayer Ag 1-alkadien-2,4-yl-2-hydroxymethyl3,4,5-trihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3007078A1 (de) 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) * 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3507019A1 (de) 1985-02-28 1986-08-28 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
US4880902A (en) 1987-08-27 1989-11-14 Shell Oil Company Copolymerization of carbon monoxide and olefin with diphosphine having heterocyclic substituents as catalyst
EP0350012A3 (de) * 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antivirale Zusammensetzung
JPH02306962A (ja) * 1989-05-19 1990-12-20 Meiji Seika Kaisha Ltd 新規n―置換―1―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
DK0477160T3 (da) * 1990-09-20 1996-05-20 Monsanto Co Fremgangsmåde til fremstilling af N-substitueret 1-deoxynojirimycin
CA2150956A1 (en) 1992-12-10 1994-06-23 Robert G. L. Shorr Glycolipid enzyme-polymer conjugates
US5429177A (en) 1993-07-09 1995-07-04 Sierra Regenators, Inc. Foil regenerator
AU1876095A (en) * 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus

Also Published As

Publication number Publication date
US6177447B1 (en) 2001-01-23
JP2014024857A (ja) 2014-02-06
AU3464797A (en) 1998-02-09
JP4564108B2 (ja) 2010-10-20
AU732552B2 (en) 2001-04-26
JP2010031062A (ja) 2010-02-12
JP2000516577A (ja) 2000-12-12
IL128036A (en) 2005-08-31
DE69735669T2 (de) 2007-03-29
JP2017122133A (ja) 2017-07-13
CA2260790A1 (en) 1998-01-22
DE69735669D1 (de) 2006-05-24
EP0912179B1 (de) 2006-04-12
JP2016056203A (ja) 2016-04-21
EP0912179A1 (de) 1999-05-06
CA2260790C (en) 2007-01-09
IL128036A0 (en) 1999-11-30
WO1998002161A1 (en) 1998-01-22

Similar Documents

Publication Publication Date Title
DE69735669D1 (de) Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
DK0891331T3 (da) N-(2-Oxoacetyl- eller sulfonyl)pyrrolidin/piperidin-2-carboxylsyrederivater med forbedret multi-lægemiddelresistensaktivitet
DE69717148D1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
BR0016693A (pt) Derivados de pirrolidina como inibidores de fosfodiesterase especìfico amp cìclico
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
RU94044677A (ru) Трехзамещенные фенильные производные, способ получения, фармацевтическая композиция
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
DK256890D0 (da) Benzo-piperidin-, -piperidyliden- og piperazinforbindelser, kompositioner indeholdende forbindelserne og fremgangsmaader til forbindelsernes fremstilling og anvendelse
NO305596B1 (no) 1-(2-okso-acetyl)-piperidin-2-karboksylsyrederivater som multi-medikamentresistente sensitivisatorer for kreftceller
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
DE60105144D1 (de) Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
BR0016687A (pt) Pirrolidinas que inibem a pde especìfica do ampc
DE59510370D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
DK1165510T3 (da) 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser
ATA903796A (de) Elektrotransporteinrichtung zur verabreichung eines als fentanylsalz oder als sufentanilsalz vorliegenden analgetischen medikaments
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
NO20006547L (no) Salter av paroxetine
PT1152762E (pt) Utilizacao de desoxipeganina no tratamento da demencia de alzheimer
NO982863L (no) Nye forbindelser med analgetisk effekt
ZA934777B (en) Novel piperidyl amides, sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis.
DK0614888T3 (da) Tetrahydrocyclopentab indol-methanaminer og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler.
EE04235B1 (et) Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks
GEP19991780B (en) Use of Pyrrolidine Derivatives for Treating Alcoholism

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties